Alpha Fetoprotein (AFP), Amniotic Fluid
Alpha Fetoprotein (AFP) is a plasma protein normally produced early in fetal life by the yolk sac and liver. Its levels decrease after birth (12 months) to a low level that is detectable in adults. Elevated serum AFP levels (beyond average levels associated with gestational age or number of fetuses) in pregnant women may indicate open Neural Tube Defect (NTD). In addition, elevated serum AFP levels in pregnant women may indicate other forms of fetal distress or malformation, which include placental malformations, ventral wall defects, fetal kidney dysfunction, and fetal death.
If used for open NTD risk assessment, incorrect estimation of gestational age can result in either under- or over-estimation of open NTD risk. Therefore, AFP testing requires accurate gestational dating for reliable risk assessment for open NTDs. Confirmatory procedures such as ultrasonography, amniography, amniotic fluid acetylcholinesterase, and amniotic fluid AFP must be used in conjunction with maternal serum AFP testing for accurate NTD risk evaluation. When using AFP in the evaluation of fetal defects, laboratories must establish their own median values for each gestational week. Absolute AFP values may vary for each lab depending on the demographics of its population, including race and maternal weight. The optimal time for screening maternal serum AFP is between the 16th and 18th weeks of pregnancy, although screening is still effective before or after this period.
AFP for prenatal screening is typically conducted in a panel, either the Triple test or the Quad Screen. The Triple test panel is: AFP, hCG, and unconjugated estriol. Some physicians or institutions have advanced to the Quad Screen, which adds another marker, inhibin A, which increases both the sensitivity and specificity of the screen.
Serum AFP levels may also be elevated in certain benign and malignant conditions not related to pregnancy. These conditions include hepatitis, cirrhosis, ataxia telangiectasia, primary hepatocellular carcinoma, and certain germ cell cancers. Therefore, AFP is also used as a tumor marker. When used as a tumor marker, increased AFP levels have been observed in patients with primary hepatocellular carcinoma, nonseminomatous testicular carcinomas, and ovarian carcinomas, as well as in other epithelial tumors, especially those of the GI tract. AFP is also increased in some nonmalignant hepatic diseases, such as viral hepatitis and active cirrhosis. Levels of less than 200 ng/mL have been reported in these benign diseases. The specificity of AFP for malignancy is greatest at levels greater than 1,000 ng/mL. Smaller (more treatable) tumors will not be detected if this threshold is used. For this reason, levels between 15-200 ng/mL should be interpreted with caution.
- Used in assessment of prenatal risk for NTD
- In conjunction with other prenatal testing markers is used in assessment of Down Syndrome and other prenatal risk screening
- Quantitative measurements aid in the management of nonseminomatuous testicular cancer
- Diagnosis of hepatocellular carcinoma, and certain germ cell neoplasms of the testes, ovary, retroperitoneum, and mediastinum
- Differential diagnosis of neonatal hepatitis versus biliary atresia in newborns
Increased in:
- Neural tube defect (Spina bifida, Anencephaly, Omphalocele)
- Fetal distress or malformation
- Placental malformations
- Ventral wall defects
- Fetal kidney dysfunction
- Hepatitis
- Cirrhosis
- Ataxia telangiectasia
- Primary hepatocellular carcinoma
- Some nonseminomatous germ cell cancers of ovary and testis
- Esophagus or duodenal atresia
- Meckel's syndrome
- Fetal hepatic necrosis due to viral infection
Decreased in:
- Down's syndrome
- Trisomy 18
Male and non-pregnant female: ≤ 6.1 ng/mL
| Gestational Week | ng/mL or mcg/L |
| 14 | 25.6 |
| 15 | 29.9 |
| 16 | 34.8 |
| 17 | 40.6 |
| 18 | 47.3 |
| 19 | 55.1 |
| 20 | 64.3 |
| 21 | 74.9 |
Serum (SST) , Amniotic Fluid.
Stability
- Ambient - 7 days
- Refrigerated - 7 days
- Frozen - 60 days (Serum only)
- Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12. [PMID: 15508073]
- Expert Rev Anticancer Ther. 2002 Dec;2(6):709-35. [PMID: 12503217]
- Expert Rev Anticancer Ther. 2002 Dec;2(6):709-35. [PMID: 12503217]
- Eur J Obstet Gynecol Reprod Biol. 1996 Mar;65(1):3-6. [PMID: 8706953]
- Curr Opin Obstet Gynecol. 1997 Apr;9(2):113-20. [PMID: 9204233]
- Clin Lab Med. 2003 Jun;23(2):385-94, ix. [PMID: 12848450]
- Clin Chim Acta. 2002 Oct;324(1-2):1-11. [PMID: 12204419]
- Semin Perinatol. 2005 Aug;29(4):203-8. [PMID: 16104669]
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757.